Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2013

01-06-2013 | Article

Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes

Authors: M. N. Pham, H. Kolb, T. Battelino, J. Ludvigsson, P. Pozzilli, F. Zivehe, M. Roden, T. Mandrup-Poulsen, N. C. Schloot, European C-Peptide Trial

Published in: Diabetologia | Issue 6/2013

Login to get access

Abstract

Aims/hypothesis

Cytokines may promote or inhibit disease progression in type 1 diabetes. We investigated whether systemic proinflammatory, anti-inflammatory and regulatory cytokines associated differently with fasting and meal-stimulated beta cell function in patients with longer term type 1 diabetes.

Methods

The beta cell function of 118 patients with type 1 diabetes of duration of 0.75–4.97 years was tested using a standardised liquid mixed meal test (MMT). Serum samples obtained at −5 to 120 min were analysed by multiplex bead-based technology for proinflammatory (IL-6, TNF-α), anti-inflammatory (IL-1 receptor antagonist [IL-1RA]) and regulatory (IL-10, TGF-β1–3) cytokines, and by standard procedures for C-peptide. Differences in beta cell function between patient groups were assessed using stepwise multiple regression analysis adjusting for sex, age, duration of diabetes, BMI, HbA1c and fasting blood glucose.

Results

High fasting systemic concentrations of the proinflammatory cytokines IL-6 and TNF-α were associated with increased fasting and stimulated C-peptide concentrations even after adjustment for confounders (p < 0.03). Interestingly, increased concentrations of anti-inflammatory/regulatory IL-1RA, IL-10, TGF-β1 and TGF-β2 were associated with lower fasting and stimulated C-peptide levels (p < 0.04), losing significance on adjustment for anthropometric variables. During the MMT, circulating concentrations of IL-6 and TNF-α increased (p < 0.001) while those of IL-10 and TGF-β1 decreased (p < 0.02) and IL-1RA and TGF-β2 remained unchanged.

Conclusions/interpretation

The association between better preserved beta cell function in longer term type 1 diabetes and increased systemic proinflammatory cytokines and decreased anti-inflammatory and regulatory cytokines is suggestive of ongoing inflammatory disease activity that might be perpetuated by the remaining beta cells. These findings should be considered when designing immune intervention studies aimed at patients with longer term type 1 diabetes and residual beta cell function.
Appendix
Available only for authorised users
Literature
1.
Bettini M, Vignali DA (2011) T cell-driven initiation and propagation of autoimmune diabetes. Curr Opin Immunol 23:754–760PubMedCrossRef
2.
Varanasi V, Avanesyan L, Schumann DM, Chervonsky AV (2012) Cytotoxic mechanisms employed by mouse T cells to destroy pancreatic β-cells. Diabetes 61:2862–2870PubMedCrossRef
3.
Rabinovitch A, Suarez-Pinzon WL (1998) Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 55:1139–1149PubMedCrossRef
4.
Donath MY, Størling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T (2008) Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 29:334–350PubMedCrossRef
5.
Mandrup-Poulsen T, Pickersgill LMS, Donath MY (2010) Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6:158–166PubMedCrossRef
6.
Wållberg M, Wong FS, Green EA (2011) An islet-specific pulse of TGF-β abrogates CTL function and promotes β cell survival independent of Foxp3+ T cells. J Immunol 186:2543–2551PubMedCrossRef
7.
Tai N, Yasuda H, Xiang Y et al (2011) IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol 139:336–349PubMedCrossRef
8.
Ardestani A, Sauter NS, Paroni F et al (2011) Neutralizing interleukin-1beta (IL-1beta) induces beta-cell survival by maintaining PDX1 protein nuclear localization. J Biol Chem 286:17144–17155PubMedCrossRef
9.
Rachmiel M, Bloch O, Bistritzer T et al (2006) TH1/TH2 cytokine balance in patients with both type 1 diabetes mellitus and asthma. Cytokine 34:170–176PubMedCrossRef
10.
Christen U, von Herrath MG (2004) Manipulating the type 1 vs type 2 balance in type 1 diabetes. Immunol Res 30:309–325PubMedCrossRef
11.
Karlsson MG, Lawesson SS, Ludvigsson J (2000) Th1-like dominance in high-risk first-degree relatives of type I diabetic patients. Diabetologia 43:742–749PubMedCrossRef
12.
Pfleger C, Mortensen HB, Hansen L et al (2008) Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 57:929–937PubMedCrossRef
13.
Pfleger C, Kaas A, Hansen L et al (2008) Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 128:57–65PubMedCrossRef
14.
Kaas A, Pfleger C, Kharagjitsingh AV et al (2012) Association between age, IL-10, IFNγ, stimulated C-peptide and disease progression in children with newly diagnosed type 1 diabetes. Diabet Med 29:734–741PubMedCrossRef
15.
Han D, Leyva CA, Matheson D et al (2011) Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. Clin Immunol 139:290–301PubMedCrossRef
16.
Peluso I, Raguzzini A, Villano DV et al (2012) High fat meal increase of IL-17 is prevented by ingestion of fruit juice drink in healthy overweight subjects. Curr Pharm Des 18:85–90PubMedCrossRef
17.
Poppitt SD, Keogh GF, Lithander FE et al (2008) Postprandial response of adiponectin, interleukin-6, tumor necrosis factor-alpha, and C-reactive protein to a high-fat dietary load. Nutrition 24:32232–32239CrossRef
18.
Nappo F, Esposito K, Cioffi M et al (2002) Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39:1145–1150PubMedCrossRef
19.
Esposito K, Ciotola M, Sasso FC et al (2007) Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. Nutr Metab Cardiovasc Dis 17:274–279PubMedCrossRef
20.
Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31:1966–1971PubMedCrossRef
21.
Pham MN, Hawa MI, Pfleger C et al (2011) Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 54:1630–1638PubMedCrossRef
22.
Highfill SL, Kelly RM, O'Shaughnessy MJ et al (2009) Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 114:693–701PubMedCrossRef
23.
Olivieri A, De Angelis S, Dionisi S et al (2010) Serum transforming growth factor β1 during diabetes development in non-obese diabetic mice and humans. Clin Exp Immunol 162:407–414PubMedCrossRef
24.
Foulis AK, Farquharson MA (1986) Aberrant expression of HLA-DR antigens by insulin-containing beta-cells in recent-onset type I diabetes mellitus. Diabetes 35:1215–1224PubMedCrossRef
25.
Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169–2180PubMedCrossRef
26.
Jörns A, Rath KJ, Terbish T et al (2010) Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology 151:3555–3565PubMedCrossRef
27.
Schloot NC, Hanifi-Moghaddam P, Goebel C et al (2002) Serum IFN-gamma and IL-10 levels are associated with disease progression in non-obese diabetic mice. Diabetes Metabol Res Rev 18:64–70CrossRef
28.
Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489PubMedCrossRef
29.
Parsa R, Andresen P, Gillett A et al (2012) Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice. Diabetes 61:2881–2892PubMedCrossRef
30.
Subramanian L, Blumenfeld H, Tohn R et al (2012) NKT cells stimulated by long fatty acyl chain sulfatides significantly reduces the incidence of type 1 diabetes in nonobese diabetic mice. PLoS One 7:e37771PubMedCrossRef
31.
Yi Z, Diz R, Martin AJ et al (2012) Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies. Diabetes 61:2871–2880PubMedCrossRef
Metadata
Title
Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes
Authors
M. N. Pham
H. Kolb
T. Battelino
J. Ludvigsson
P. Pozzilli
F. Zivehe
M. Roden
T. Mandrup-Poulsen
N. C. Schloot
European C-Peptide Trial
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-013-2883-3

Other articles of this Issue 6/2013

Diabetologia 6/2013 Go to the issue

Article

Distinct and opposing roles for the phosphatidylinositol 3-OH kinase catalytic subunits p110α and p110β in the regulation of insulin secretion from rodent and human beta cells

Article

Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice

Article

Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease

Article

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice

Commentary

Should more attention be paid to school performance in children and adolescents with diabetes?

Article

The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D)
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits